Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

When blood is clotted, alpha(2)-plasmin inhibitor (alpha(2)PI) is cross-linked to fibrin by activated fibrin-stabilizing factor (activated coagulation Factor XIII, plasma transglutaminase). The amount of cross-linked alpha(2)-PI is proportional to the amount of alpha(2)PI present at the time of clotting. Plasma from a patient with congenital deficiency of alpha(2)PI was supplemented with various amounts of purified alpha(2)PI. Clots were prepared from these plasmas and were suspended in plasma containing a normal concentration of alpha(2)PI, and spontaneous clot lysis was observed. When the clot was formed in the presence of calcium ions and thereby allowing cross-linking to occur, the rate and extent of fibrinolysis were found to be inversely proportional to the concentrations of alpha(2)PI present in the clot at the time of clotting. When the clot was formed in the absence of calcium ions so that no cross-linking occurred, the clot underwent fibrinolysis at similar rates, regardless of the concentrations of alpha(2)PI in the clot. When the clot formed in the presence of calcium ions was squeezed and washed to remove unbound proteins before being suspended in plasma, the extent of fibrinolysis was also inversely proportional to the amount of alpha(2)PI cross-linked to fibrin. Similar results were obtained when the clot was suspended in buffered saline instead of plasma. These observations suggest that spontaneous fibrinolysis is mainly carried out by plasminogen/plasminogen activator bound to fibrin, and this fibrinolysis caused by fibrin-associated activation of plasminogen was mainly inhibited by alpha(2)PI cross-linked to fibrin. To further support this concept, alpha(2)PI treated with activated fibrin-stabilizing factor and that had lost most of its cross-linking capacity was used in similar experiments. This modified alpha(2)PI had the same inhibitory activity on plasmin as the native inhibitor, but gave significantly less inhibition of fibrinolysis in every experiment, particularly when the clot was compacted by platelet-mediated clot retraction or by squeezing. Thus, it was concluded that alpha(2)PI cross-linked to fibrin plays a significant role in inhibition of physiologically occurring fibrinolysis. It is further suggested that the absence of cross-linked alpha(2)PI contributes to accelerated fibrinolysis and hemorrhagic tendency in patients with congenital deficiency of fibrin-stabilizing factor.

[1]  T. Tamaki,et al.  Cross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor , 1981 .

[2]  Y. Sakata,et al.  Influence of α2-plasmin inhibitor on adsorption of plasminogen to fibrin , 1980 .

[3]  K. Tateno,et al.  Fibrinolytic states in a patient with congenital deficiency of alpha 2-plasmin inhibitor. , 1980, Blood.

[4]  Y. Sakata,et al.  Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. , 1980, The Journal of clinical investigation.

[5]  Y. Sakata,et al.  Congenital Deficiency of α2-Plasmin Inhibitor Associated with Severe Hemorrhagic Tendency , 1979 .

[6]  H. Saito,et al.  Inhibitory spectrum of alpha 2-plasmin inhibitor. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Aoki,et al.  Assay of alpha2-plasmin inhibitor activity by means of a plasmin specific tripeptide substrate. , 1978, Thrombosis research.

[8]  Y. Sakata,et al.  Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. , 1978, The Journal of clinical investigation.

[9]  B. Wiman,et al.  Fast-acting plasmin inhibitor in human plasma. , 1978, Blood.

[10]  Aoki Nobuo,et al.  The α2-plasmin inhibitor levels in liver diseases , 1978 .

[11]  N. Aoki,et al.  Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin. , 1978, Thrombosis and haemostasis.

[12]  N. Aoki,et al.  Inhibition of proteases in coagulation, kinin-forming and complement systems by alpha2-plasmin inhibitor. , 1977, Journal of biochemistry.

[13]  M. Matsuda,et al.  The behavior of alpha2-plasmin inhibitor in fibrinolytic states. , 1977, The Journal of clinical investigation.

[14]  I. Clemmensen,et al.  The primary inhibitor of plasmin in human plasma. , 1976, The Biochemical journal.

[15]  N. Aoki,et al.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. , 1976, The Journal of biological chemistry.

[16]  D. Collen Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. , 1976, European journal of biochemistry.

[17]  D. Mosher Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. , 1975, The Journal of biological chemistry.

[18]  S. Pizzo,et al.  Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. , 1973, The Journal of biological chemistry.

[19]  G. David Solid state lactoperoxidase: a highly stable enzyme for simple, gentle iodination of proteins. , 1972, Biochemical and biophysical research communications.

[20]  S. I. Chung,et al.  Kinetic studies with transglutaminases. The human blood enzymes (activated coagulation factor 13 and the guinea pig hair follicle enzyme. , 1972, The Journal of biological chemistry.

[21]  B. Wiman,et al.  Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. , 1972, Biochimica et biophysica acta.

[22]  R. Lundblad A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme wtih phenylmethylsulfonyl fluoride. , 1971, Biochemistry.

[23]  K. Weber,et al.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. , 1969, The Journal of biological chemistry.

[24]  N. Aoki Natural inhibitors of fibrinolysis. , 1979, Progress in cardiovascular diseases.

[25]  L. Lorand,et al.  Fibrin-stabilizing factor (factor XIII). , 1976, Methods in enzymology.

[26]  H. Bohn,et al.  Eine quantitative Bestimmung von Faktor XIII mit Anti-Faktor-XIII-Serum , 1968, Thrombosis and Haemostasis.